Dr KK Aggarwal
Selinexor (Xpovio) tablet in
combination with dexamethasone has received FDA approval as treatment option
for the adult patients with multiple myeloma with no available therapy.
Indication: Treatment of adult patients with relapsed
refractory multiple myeloma who have received at least four prior therapies
and whose disease is resistant to several other forms of treatment, including
at least two proteasome inhibitors, at least two immunomodulatory agents, and
an anti-CD38 monoclonal antibody
Side effects: Leukopenia, neutropenia, thrombocytopenia,
anemia, vomiting, nausea, fatigue, diarrhea, fever, decreased appetite and
weight, constipation, upper respiratory tract infections and hyponatremia.
Precautions
· Monitor
patients for low blood counts, platelets and sodium levels.
· Avoid
taking this drug along with other medications that may cause dizziness or
confusion and avoid situations where dizziness may be a problem.
· Health
care professionals should optimize the patient’s hydration status, blood counts
and other medications to avoid dizziness or confusion.
(Source: FDA)
Dr KK Aggarwal
Padma Shri Awardee
President Elect Confederation of
Medical Associations in Asia and Oceania
(CMAAO)
Group Editor-in-Chief IJCP Publications
President Heart Care Foundation of
India
Past National President
IMA
No comments:
Post a Comment